Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2025 Feb 26

PMID 40005338

Authors

Valentina Perrone

Marcello Usala

Chiara Veronesi

Maria Cappuccilli

Luca Degli Esposti

Affiliations

Soon will be listed here.

Abstract

: This analysis described rifaximin utilization in Italian patients with hepatic encephalopathy (HE). Although rifaximin is effective in preventing HE relapses, therapeutic management and prescriptive attitudes might be improved. : Between Oct-2020 and Sep-2021, approximately 12.7 million citizens, patients hospitalized for HE, were identified through the ICD-9-CM code 572.2. Among those discharged alive, utilization of rifaximin 550 mg vs. rifaximin 200 mg for two months post-admission was compared. : Of 634 patients hospitalized for HE, 447 (70.5%) were discharged alive. In the two following months, 276 (61.7%) received rifaximin, of whom 117 (26.2%) received rifaximin 550 mg (two daily tablets) and 159 (35.6%) received rifaximin 200 mg (six daily tablets); among 171 patients without rifaximin, 56 (32.7%) received lactulose/lactitol. One year after rifaximin initiation, patients on rifaximin 550 mg (vs. 200 mg) were more frequently persistent (i.e., did not interrupt therapy) (78.6% vs. 46.9%, < 0.001), showed a lower switching proportion (21.4% vs. 40.7%, < 0.050), and had a mean monthly dose closer to the recommendations of 36,000 mg/month (~33,000 mg/month vs. 11,629 mg/month, respectively). : This analysis suggests suboptimal rifaximin utilization for HE management. Although rifaximin 550 mg is the only formulation with specific indication and reimbursability to prevent HE relapses in Italy, rifaximin 200 mg is more largely used. The need to improve rifaximin prescribing choices is supported by higher persistence, lower switching rates, and average doses aligned to recommendations in patients treated with rifaximin 550 mg.

References

Rahimi R, Brown K, Flamm S, Brown Jr R . Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Am J Med. 2021; 134(11):1330-1338. DOI: 10.1016/j.amjmed.2021.06.007. View

Sherwin L, Ross D, Matteson-Kome M, Bechtold M, Deroche C, Wakefield B . Patient Perspectives on Short-Course Pharmacotherapy: Barriers and Facilitators to Medication Adherence. J Patient Exp. 2020; 7(5):726-733. PMC: 7705821. DOI: 10.1177/2374373519882230. View

Shawcross D, Sharifi Y, Canavan J, Yeoman A, Abeles R, Taylor N . Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2010; 54(4):640-9. DOI: 10.1016/j.jhep.2010.07.045. View

Volk M, Burne R, Guerin A, Shi S, Joseph G, Heimanson Z . Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. J Med Econ. 2021; 24(1):202-211. DOI: 10.1080/13696998.2021.1877148. View

Stoll A, Guido M, Pence A, Gentene A . Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy. Ann Pharmacother. 2022; 57(2):133-140. DOI: 10.1177/10600280221100537. View

Idalsoaga F, Robles C, Ortiz A, Corsi O, Fuentes-Lopez E, Diaz L . Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy. Therap Adv Gastroenterol. 2024; 17:17562848241254267. PMC: 11135071. DOI: 10.1177/17562848241254267. View

Sepehrinezhad A, Moghaddam N, Shayan N, Negah S . Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis. PLoS One. 2024; 19(9):e0307899. PMC: 11371226. DOI: 10.1371/journal.pone.0307899. View

Calanni F, Renzulli C, Barbanti M, Viscomi G . Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014; 67(9):667-70. DOI: 10.1038/ja.2014.106. View

Bannister C, Orr J, Reynolds A, Hudson M, Conway P, Radwan A . Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clin Ther. 2016; 38(5):1081-1089.e4. DOI: 10.1016/j.clinthera.2016.03.033. View

10.

Parisse S, Lai Q, Martini F, Martini A, Ferri F, Mischitelli M . Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy. J Clin Med. 2023; 12(21). PMC: 10647372. DOI: 10.3390/jcm12216871. View

11.

Pandico F, Citarella A, Cammarota S, Bernardi F, Claar E, Coppola C . Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy. J Clin Med. 2023; 12(13). PMC: 10342713. DOI: 10.3390/jcm12134515. View

12.

Bass N, Mullen K, Sanyal A, Poordad F, Neff G, Leevy C . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362(12):1071-81. DOI: 10.1056/NEJMoa0907893. View

13.

Zacharias H, Kamel F, Tan J, Kimer N, Gluud L, Morgan M . Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023; 7:CD011585. PMC: 10360160. DOI: 10.1002/14651858.CD011585.pub2. View

14.

Aller M, Arias N, Blanco-Rivero J, Arias J, Arias J . Hepatic encephalopathy: Sometimes more portal than hepatic. J Gastroenterol Hepatol. 2018; 34(3):490-494. DOI: 10.1111/jgh.14514. View

15.

Badal B, Bajaj J . Hepatic Encephalopathy: Diagnostic Tools and Management Strategies. Med Clin North Am. 2023; 107(3):517-531. DOI: 10.1016/j.mcna.2023.01.003. View

16.

Sharma B, Sharma P, Lunia M, Srivastava S, Goyal R, Sarin S . A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013; 108(9):1458-63. DOI: 10.1038/ajg.2013.219. View

17.

Azhari H, Swain M . Role of Peripheral Inflammation in Hepatic Encephalopathy. J Clin Exp Hepatol. 2018; 8(3):281-285. PMC: 6175767. DOI: 10.1016/j.jceh.2018.06.008. View

18.

McPhail M, Bajaj J, Thomas H, Taylor-Robinson S . Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2010; 4(3):365-78. DOI: 10.1586/egh.10.32. View

19.

Infante R, Ericsson C, Jiang Z, Ke S, Steffen R, Riopel L . Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol. 2004; 2(2):135-8. DOI: 10.1016/s1542-3565(03)00322-7. View

20.

Garattini L, Padula A . 'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?. Appl Health Econ Health Policy. 2016; 15(1):1-3. DOI: 10.1007/s40258-016-0240-7. View